Market closedNon-fractional

Cara Therapeutics/CARA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Cara Therapeutics

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Ticker

CARA

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Stamford, United States

Employees

55

CARA Metrics

BasicAdvanced
$15M
Market cap
-
P/E ratio
-$2.26
EPS
0.73
Beta
-
Dividend rate
$15M
0.73
5.381
4.816
151.666
152.404
-46.83%
-62.20%
-147.29%
0.872
0.5
0.5
-0.162
-60.83%
43.90%
-49.16%
98.22%

What the Analysts think about CARA

Analyst Ratings

Majority rating from 5 analysts.
Buy

CARA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,457.14% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.1M
-30.00%
Net income
-$31M
-5.26%
Profit margin
-1,457.14%
35.34%

CARA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 40.70%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.58
-$0.52
-$0.59
-$0.56
-
Expected
-$0.54
-$0.52
-$0.41
-$0.40
-$0.27
Surprise
7.74%
0.00%
43.20%
40.70%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cara Therapeutics stock?

Cara Therapeutics (CARA) has a market cap of $15M as of July 06, 2024.

What is the P/E ratio for Cara Therapeutics stock?

The price to earnings (P/E) ratio for Cara Therapeutics (CARA) stock is 0 as of July 06, 2024.

Does Cara Therapeutics stock pay dividends?

No, Cara Therapeutics (CARA) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Cara Therapeutics dividend payment date?

Cara Therapeutics (CARA) stock does not pay dividends to its shareholders.

What is the beta indicator for Cara Therapeutics?

Cara Therapeutics (CARA) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Cara Therapeutics stock

Buy or sell Cara Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing